Last updated: February 13, 2026
Overview
NDC 24208-0503 corresponds to Human Papillomavirus (HPV) vaccine, types 6, 11, 16, and 18, marketed as Gardasil 9. This vaccine prevents certain strains of HPV associated with cervical, anal, head, neck, and other cancers. It is a significant product in the vaccine market with high demand owing to its prophylactic benefits and widespread adoption for cervical cancer prevention.
Market Size and Growth Drivers
Global HPV Vaccine Market: The global market was valued at approximately $4.8 billion in 2022. Projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2027. Key drivers include increasing awareness of HPV-related cancers, expansion of immunization programs, and approval for broader age groups.
Regional Insights:
- North America: Largest market, driven by high vaccination rates, reimbursement policies, and awareness. Market size over $2 billion in 2022.
- Asia-Pacific: Fastest growth, fueled by rising healthcare infrastructure and vaccination programs. Expected CAGR of 12%.
- Europe: Mature market, stable demand, with emerging markets in Eastern Europe.
Market Penetration and Competition:
- Dominant players: Merck (Gardasil 9), GlaxoSmithKline (Cervarix).
- Market penetration varies by country, with some nations achieving vaccination rates exceeding 70%. In others, coverage remains below 30%.
Pricing Landscape
Ex-Factory Price Range:
- United States: The listed wholesale acquisition cost (WAC) for Gardasil 9 varies between $140 and $180 per dose.
- International: Prices are lower, often between $50 and $100 per dose, due to tiered pricing and negotiated procurement contracts.
Reimbursement and Payer Dynamics:
- In the U.S., insurance coverage and Medicaid programs significantly influence actual prices paid.
- CDC's ACIP recommendations have increased insurance coverage, positively affecting sales volume.
Pricing Trends:
- A gradual decrease in per-dose price observed in recent years, driven by increased competition, manufacturing efficiencies, and market saturation.
- No recent price hikes for Gardasil 9 documented since its approval in 2014.
Regulatory and Policy Impact
FDA Approval & Recommendations:
- Approved in 2014 for males and females aged 9-45.
- Subject to continued review and post-market surveillance, with manufacturing standards maintained under FDA and CDC guidelines.
WHO and Global Policies:
- WHO recommends HPV vaccination as part of national immunization programs.
- Several low- and middle-income countries are integrating HPV vaccines through Gavi-supported programs, impacting global demand.
Reimbursement Policies:
- In the U.S., CDC recommends vaccination at ages 11-12.
- Insurance and government programs subsidize vaccine costs, impacting profit margins and access.
Market Entry and Competitive Outlook
Barriers to Entry:
- High R&D costs for developing HPV vaccines.
- Regulatory approval processes.
- Established market dominance by Merck and GSK.
Emerging Competition:
- Biosimilar or next-generation HPV vaccines are in early development phases.
- Potential for combination vaccines to capture broader indications and extend lifecycle.
Price Projection (2023–2027)
| Year |
Estimated Per Dose Price (USD) |
Market Size (USD Billion) |
Notes |
| 2023 |
$130 - $150 |
$4.8 billion |
Stable demand, slight price decline |
| 2024 |
$125 - $145 |
$5.2 billion |
Increased vaccination coverage |
| 2025 |
$120 - $140 |
$5.5 billion |
Market saturation in mature regions |
| 2026 |
$115 - $135 |
$5.8 billion |
Entry of biosimilars delayed, demand remains high |
| 2027 |
$110 - $130 |
$6.0 billion |
Consolidation, price stabilization |
Note: Price range reflects negotiated retail prices, PQS (Publicly Quoted Supply) prices, and manufacturing efficiencies.
Key Takeaways
- The HPV vaccine market is growing steadily, with Gardasil 9 leading due to its broader strain coverage.
- Price per dose in the U.S. remains around $140-$180 but is trending downward due to increasing competition and market saturation.
- Global demand is expanding, especially in low- and middle-income nations through Gavi programs.
- The market is consolidating, with limited imminent entrants due to high development costs and regulatory hurdles.
FAQs
1. What factors influence the pricing of Gardasil 9 globally?
Pricing depends on regulatory environment, procurement agency negotiations, reimbursement policies, and regional healthcare infrastructure. Tiered pricing strategies are common, with higher-income countries paying more.
2. How does the competitive landscape affect future prices?
Presence of biosimilars or next-generation vaccines could pressure existing prices downward. Market entry barriers sustain high prices, but patent expirations or legal challenges could lower them.
3. Are there restrictions on vaccine distribution?
Distribution is influenced by regulatory approvals, supply chain logistics, and national immunization policies. In some regions, cold chain requirements limit access.
4. What is the impact of policy changes on market size?
Policy shifts towards mandatory vaccination in schools or inclusion in national programs can significantly expand market size, especially in developing countries.
5. How do patent expirations influence the market?
Patent expiration can lead to generics or biosimilar entry, putting downward pressure on prices and market share distribution, primarily in mature regions.
Citations
[1] MarketResearch.com, "Global HPV Vaccines Market," 2023.
[2] IQVIA, "Healthcare Data & Insights," 2023.
[3] CDC, "Recommendations for HPV Vaccination," 2022.
[4] Gavi, "HPV Vaccine Procurement Data," 2022.
[5] FDA, "Gardasil 9 Approval Notice," 2014.
